Chemical Component Summary

FormulaC9 H13 N3 O6
Molecular Weight259.216
Isomeric SMILESC1=CN(C(=O)N=C1NO)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O

Chemical Details

Formal Charge0
Atom Count31
Chiral Atom Count4
Bond Count32
Aromatic Bond Count0

Drug Info: DrugBank

DrugBank IDDB15660 
Groups experimental
DescriptionN4-Hydroxyctidine, or EIDD-1931, is a ribonucleoside analog which induces mutations in RNA virions.[A193008,A193011] N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of bacteria and phage.[A193023] It has shown antiviral activity against Venezuelan equine encephalitis virus,[A193008] and the human coronavirus HCoV-NL63 _in vitro_.[A193017] N4-hydroxycytodine has been shown to inhibit SARS-CoV-2 as well as other human and bat coronaviruses in mice and human airway epithelial cells.[A193014] It is orally bioavailable in mice and distributes into tissue before becoming the active 5’-triphosphate form, which is incorporated into the genome of new virions, resulting in the accumulation of inactivating mutations.[A193011] In non-human primates, N4-hydroxycytidine was poorly orally bioavailable.[A193026] A [remdesivir] resistant mutant mouse hepatitis virus has also been shown to have increased sensitivity to N4-hydroxycytidine.[A193014] The prodrug of N4-hydroxycytidine, [EIDD-2801], is also being investigated for its broad spectrum activity against the coronavirus family of viruses.[A193014]
  • Beta-D-N4-hydroxycytidine
  • N4-Hydroxycytidine
  • beta-D-N-4-Hydroxycytidine
  • β-D-N4-hydroxycytidine
  • NHC
IndicationN4-hydroxycytidine and its prodrug [EIDD-2801] is being studied for its activity against a number of viral infections including influenza, MERS-CoV, and SARS-CoV-2.[A193014, A193029]
  • Carbohydrates
  • Cytosine Nucleotides
  • Experimental Unapproved Treatments for COVID-19
  • Glycosides
  • Nucleic Acids, Nucleotides, and Nucleosides
CAS number3258-02-4

Related Resource References

Resource NameReference
PubChem 197020
ChEBI CHEBI:180654